NewsGlobeNewswire
Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)
· Published
Article summary
Longeveron announces updated results of ELPIS II, the Company's trial evaluating its stem cell therapy in HLHS.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…